AzurRx BioPharma (AZRX) Competitors

Unity Biotechnology (NASDAQ:UBX) and AzurRx BioPharma (NASDAQ:AZRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.

Do analysts prefer UBX or AZRX?

Unity Biotechnology currently has a consensus price target of $5.33, indicating a potential upside of 438.72%. Given Unity Biotechnology's stronger consensus rating and higher possible upside, equities analysts plainly believe Unity Biotechnology is more favorable than AzurRx BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unity Biotechnology	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
AzurRx BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is UBX or AZRX more profitable?

Unity Biotechnology's return on equity of -119.70% beat AzurRx BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unity Biotechnology	N/A	-119.70%	-45.86%
AzurRx BioPharma	N/A	-482.96%	-258.47%

Do institutionals & insiders believe in UBX or AZRX?

29.5% of Unity Biotechnology shares are held by institutional investors. Comparatively, 6.3% of AzurRx BioPharma shares are held by institutional investors. 5.8% of Unity Biotechnology shares are held by insiders. Comparatively, 7.3% of AzurRx BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Which has preferable valuation and earnings, UBX or AZRX?

AzurRx BioPharma has lower revenue, but higher earnings than Unity Biotechnology. Unity Biotechnology is trading at a lower price-to-earnings ratio than AzurRx BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unity Biotechnology	$240K	69.58	-$39.86M	-$1.53	-0.65
AzurRx BioPharma	N/A	N/A	-$32.67M	-$11.50	-0.04

Does the media refer more to UBX or AZRX?

In the previous week, Unity Biotechnology had 5 more articles in the media than AzurRx BioPharma. MarketBeat recorded 5 mentions for Unity Biotechnology and 0 mentions for AzurRx BioPharma. AzurRx BioPharma's average media sentiment score of 0.00 beat Unity Biotechnology's score of -0.98 indicating that AzurRx BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Unity Biotechnology	Negative
AzurRx BioPharma	Neutral

Which has more risk & volatility, UBX or AZRX?

Unity Biotechnology has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, AzurRx BioPharma has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.

Does the MarketBeat Community prefer UBX or AZRX?

AzurRx BioPharma received 45 more outperform votes than Unity Biotechnology when rated by MarketBeat users. Likewise, 74.26% of users gave AzurRx BioPharma an outperform vote while only 67.16% of users gave Unity Biotechnology an outperform vote.

Company	Underperform	Outperform
Unity Biotechnology	Outperform Votes 180 67.16%	Underperform Votes 88 32.84%
AzurRx BioPharma	Outperform Votes 225 74.26%	Underperform Votes 78 25.74%

Summary

Unity Biotechnology beats AzurRx BioPharma on 9 of the 16 factors compared between the two stocks.